Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Lung 100: Avelumab vs Chemotherapy in First-Line NSCLC
NCT02576574Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Oct 2015
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 42
01
Overview
Phase 3, randomised, open-label trial of avelumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by EMD Serono. Primary endpoints: Progression Free Survival up to 71.5 months and Overall Survival up to 71.5 months. Started Oct 2015; status: completed.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02576574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576574.